VERTEX PHARMACEUTICALS INCORPORATED lobbying for VERTEX PHARMACEUTICALS INCORPORATED

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 13, 2026

Expenses

$1,110,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Massachusetts

Official filing document

Government bodies contacted 10

Centers For Medicare and Medicaid Services (CMS)
Congressional Budget Office (CBO)
Food & Drug Administration (FDA)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
Office of Management & Budget (OMB)
SENATE
U.S. Trade Representative (USTR)
Vice President of the U.S.
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 5

HR 6423
HELP Copays Act
S 864
HELP Copays Act
HR 1227
Alternatives to PAIN Act
S 475
Alternatives to PAIN Act
HR 1414
Cameron’s Law

Lobbying activity 7

Health Issues

Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.

Medicare/Medicaid

Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.

Taxation/Internal Revenue Code

Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit; Restoration of Sec 174 R&D Expense Deductibility.

Budget/Appropriations

Education about non-opioid pain therapies and patient access to non-opioid medicines; Education on alternative funding programs; Education on the Million Veteran Program at the VA.

Trade (domestic/foreign)

Intellectual property reforms to address unfair trade practices in Argentina and Russia.

Pharmacy

Issues related to the National Defense Authorization Act - access to non-opioids for service members and their families; Issues related to the NDAA S.Amdt.3841 BIOSECURE Act.

Veterans

Issues related to veteran's access to non-opioid alternatives and implementation of report language in the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (PL 119-37).